IceCure Medical Set to Present ProSense® Cryoablation Progress
![IceCure Medical Set to Present ProSense® Cryoablation Progress](https://investorshangout.com/images/blog/ihnews-IceCure%20Medical%20Set%20to%20Present%20ProSense%C2%AE%20Cryoablation%20Progress.jpg)
IceCure Medical Prepares for FDA Advisory Panel Meeting
IceCure Medical Ltd (NASDAQ: ICCM) has announced an important meeting involving the U.S. Food and Drug Administration (FDA). The FDA's Medical Device Advisory Committee Panel will convene to discuss ProSense®, a cryoablation technology aimed at providing an alternative solution for patients with early-stage low-risk breast cancer.
Understanding ProSense® and Its Significance
The ProSense® Cryoablation System is designed to treat tumors by utilizing extreme cold to effectively freeze and destroy tissue. This innovative approach is particularly relevant for the approximately 70,000 women diagnosed annually in the U.S. with early-stage low-risk breast cancer. IceCure aims to demonstrate that ProSense® is a viable alternative to traditional surgical options, such as lumpectomy.
Public Forum to Gain Insights for Stakeholders
The upcoming panel meeting serves as a platform for stakeholders, including patients, physicians, and payors, to engage in discussions. IceCure's CEO, Eyal Shamir, expressed the importance of this forum, stating it allows diverse perspectives to assess the potential benefits of ProSense® cryoablation.
Anticipated Outcomes and Next Steps
Following the Advisory Panel, the FDA is expected to render a decision regarding the marketing clearance of ProSense® by early 2025. This timeline is critical as it could pave the way for broader implementation of the technology in clinical settings.
Composition of the Advisory Panel
The panel will consist of professionals including breast surgeons and interventional radiologists. They will review extensive data from various clinical trials, such as the ICE3 study—significant as it represents the largest controlled multicenter trial examining liquid nitrogen-based cryoablation.
Clinical Study Results Highlighting ProSense® Efficacy
Preliminary findings from the ICE3 study illustrate promising results: 96.3% of patients treated with the ProSense® cryoablation followed by adjuvant endocrine therapy remained free from local recurrence over a five-year period, with total satisfaction from both patients and healthcare providers.
The Role of IceCure Medical in Advancing Cancer Treatment
IceCure Medical is on the forefront of cancer treatment technologies, specializing in cryoablation. Their method utilizes liquid nitrogen to create effective and large lethal zones that enhance the destruction of both benign and malignant tumors. The technology is not limited to breast cancer; it encompasses applications in various cancers, including those affecting the kidney, lung, and liver.
Concluding Thoughts on the Upcoming Advisory Panel Meeting
As the FDA prepares for the Advisory Panel proceedings, IceCure will ensure transparency by releasing meeting materials to the public shortly before the event. This open approach reinforces IceCure's commitment to keeping shareholders and interested parties informed.
Frequently Asked Questions
What is the purpose of the FDA Advisory Panel meeting?
The meeting is intended to gather expert opinions on ProSense® cryoablation technology and discuss its potential as a treatment for early-stage low-risk breast cancer.
What outcomes does IceCure Medical anticipate?
IceCure expects the FDA to make a marketing clearance decision regarding ProSense® by early 2025.
Who will be part of the Advisory Panel?
The panel will include breast surgeons, interventional radiologists, and regulatory experts who will review clinical data.
How effective is ProSense® based on clinical studies?
Clinical studies indicate that over 96% of patients treated with ProSense® remained free from local tumor recurrence five years post-treatment.
What are the main advantages of using ProSense®?
The ProSense® System is minimally invasive, leads to quicker recovery times, and reduces pain and surgical risks compared to traditional surgery.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Innovative Accelerator Strengthens Space-Based Technology Ventures
- Elastic Expands Elasticsearch API to Support Hugging Face Models
- SWOOP Analytics Appoints Edward Rhemrev as European Director
- Exciting Sponsorship: Calian Joins Ottawa Senators Family
- Enhancing Contractor Safety: TAQA North Partners with ISN
- Insights into Citigroup's Growing Options Activity and Trends
- New Coalition Formed to Combat Texas Litigation Challenges
- General Motors And Hyundai: A Strategic Partnership For EV Growth
- Landscaping Services Expected to Thrive to $401.4 Billion
- Investigation Targets Moderna Investors Amid Efficacy Concerns
Recent Articles
- Leadership Changes at Color Health: Key Appointments Made
- Kroger Reports Second Quarter 2024 Results and Updates Full-Year Identical Sales Without Fuel Guidance
- Manna Tree Enhances Team with Key Promotions and New Hires
- Dow Inc. Announces Earnings Guidance for Third Quarter 2024
- Kineticos and Orthobond Join Forces to Combat Bacterial Infection
- Exploring the Evolving Global Talent Landscape by ManpowerGroup
- Mobile Health Consumer Launches Digital GLP-1 Support Programs
- Experience the Future of Communications with Bandwidth's Launch
- Sowell Management Teams Up with TIFIN AG for Growth
- American Liver Foundation Gala: Celebrating Liver Health Leaders
- Avantor Celebrates EcoVadis Bronze Medal for Sustainability Success
- Rigel Pharmaceuticals to Showcase Innovations at Healthcare Conference
- Genpact and STADA Forge Stronger Bonds to Transform Finance
- Vibram's Leadership Solidified at the 2024 UTMB Event
- Innovative Revenue Management Partnership Set to Boost Cruises
- Alaska Air Upgrades Earnings Outlook Amid Summer Travel Surge
- McDonald's Expands $5 Meal Deal - Enjoy Affordable Dining
- US Technology Leaders Engage in Energy Discussions for AI Growth
- Stellantis Announces Temporary Production Halt for Fiat 500 EV
- Discover the Stability and Growth of Realty Income's Dividends
- Stellantis and UAW Dispute: A Closer Look at Job Security
- Planning for Retirement: Is $750,000 Enough for Comfort?
- Advancements in Bispecific Antibody Drug Conjugates by 2029
- Ensemble Health Partners Celebrated Among Top Healthcare Workplaces
- Quantalytix Appoints Tadgh Spradlin as New Sales VP
- AutoNation's Analyst Coverage Sparks Interest in Key Stocks
- Insider Trades: Upstart, Insulet, and Intuit Executives Sell
- GoodLeap Unveils GoodGrid: Empowering Homeowners and the Grid
- Canada Nickel's Key Financial Support Moves Towards Success
- Revolutionizing Intelligence with Jumptuit's Genesis J2T AI
- IDB Lab Forum: Driving Sustainable Innovation and Inclusion
- Inflammatix Raises $57 Million to Enhance Infection Diagnostics
- Rising Obesity Rates Among U.S. Adults Demand Policy Changes
- Wells Fargo Predicts Significant Federal Rate Cuts Ahead
- Carvana's Disruption Strategy in the Used Vehicle Market
- Broadcom's Financial Performance and Future Growth Insights
- Exploring the Future of the Dual Containment Pipes Market
- Exploring Affordable Fintech Stocks to Consider Today
- Industrial Truck Market Growth Forecasts and Innovations Ahead
- Smart Pole Market Forecast: A Surging Future with 5G Integration
- Insight into the Expanding Hospital Lights Market
- Scatec Enters Groundbreaking Power Purchase Agreement in Egypt
- Octopus Future Generations VCT plc Reports Current NAV as 86.8 Pence
- Lilium Enhances Board with Aerospace Leader Philippe Balducchi
- Petrolympic Launches Exciting Drilling Campaign in Quebec
- Sagimet Showcases Denifanstat at MASH Summit for Liver Health
- FTI Consulting Strengthens Leadership with Consumer & Retail Expert
- Amesite Expands NurseMagic™ Pilot Programs with Healthcare Leaders
- Kelly Services Welcomes New CFO Bringing Extensive Expertise
- Skyharbour Strengthens Team with Expert Geoscientist Appointment